TNFAIP3 mutation mainly occurs in adult T‐ALL patients, and it was associated with adverse clinical outcomes for T‐ALL patients; thus, it might be a biomarker for prognostic stratification. Here, TNFAIP3 is linked to acute lymphoblastic leukemia.